nodes	percent_of_prediction	percent_of_DWPC	metapath
Citalopram—HRH1—atherosclerosis	0.436	1	CbGaD
Citalopram—CYP2B6—Simvastatin—atherosclerosis	0.0396	0.116	CbGbCtD
Citalopram—CYP2C19—Rosuvastatin—atherosclerosis	0.0271	0.0793	CbGbCtD
Citalopram—CYP2C19—Simvastatin—atherosclerosis	0.0252	0.0737	CbGbCtD
Citalopram—CYP2C19—Lovastatin—atherosclerosis	0.0246	0.0722	CbGbCtD
Citalopram—CYP2D6—Niacin—atherosclerosis	0.0242	0.0709	CbGbCtD
Citalopram—ABCB1—Ezetimibe—atherosclerosis	0.0219	0.064	CbGbCtD
Citalopram—ABCB1—Simvastatin—atherosclerosis	0.0203	0.0595	CbGbCtD
Citalopram—ABCB1—Lovastatin—atherosclerosis	0.0199	0.0582	CbGbCtD
Citalopram—ABCB1—Pravastatin—atherosclerosis	0.0199	0.0582	CbGbCtD
Citalopram—CYP2D6—Simvastatin—atherosclerosis	0.0191	0.0561	CbGbCtD
Citalopram—CYP2D6—Pravastatin—atherosclerosis	0.0187	0.0549	CbGbCtD
Citalopram—CYP2D6—Lovastatin—atherosclerosis	0.0187	0.0549	CbGbCtD
Citalopram—CYP3A4—Ezetimibe—atherosclerosis	0.0131	0.0383	CbGbCtD
Citalopram—CYP3A4—Rosuvastatin—atherosclerosis	0.0131	0.0383	CbGbCtD
Citalopram—CYP3A4—Simvastatin—atherosclerosis	0.0122	0.0356	CbGbCtD
Citalopram—CYP3A4—Pravastatin—atherosclerosis	0.0119	0.0349	CbGbCtD
Citalopram—CYP3A4—Lovastatin—atherosclerosis	0.0119	0.0349	CbGbCtD
Citalopram—Escitalopram—HRH1—atherosclerosis	0.0041	1	CrCbGaD
Citalopram—Muscle spasms—Simvastatin—atherosclerosis	0.000152	0.000941	CcSEcCtD
Citalopram—Vertigo—Lovastatin—atherosclerosis	0.000152	0.00094	CcSEcCtD
Citalopram—Angioedema—Ezetimibe—atherosclerosis	0.000152	0.000938	CcSEcCtD
Citalopram—Angiopathy—Niacin—atherosclerosis	0.000151	0.000937	CcSEcCtD
Citalopram—Leukopenia—Lovastatin—atherosclerosis	0.000151	0.000937	CcSEcCtD
Citalopram—Chills—Niacin—atherosclerosis	0.00015	0.000926	CcSEcCtD
Citalopram—Malaise—Ezetimibe—atherosclerosis	0.00015	0.000926	CcSEcCtD
Citalopram—Vision blurred—Simvastatin—atherosclerosis	0.000149	0.000922	CcSEcCtD
Citalopram—Arrhythmia—Niacin—atherosclerosis	0.000149	0.000922	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Rosuvastatin—atherosclerosis	0.000148	0.000918	CcSEcCtD
Citalopram—Tremor—Simvastatin—atherosclerosis	0.000148	0.000917	CcSEcCtD
Citalopram—Alopecia—Niacin—atherosclerosis	0.000147	0.000912	CcSEcCtD
Citalopram—Chills—Pravastatin—atherosclerosis	0.000147	0.000912	CcSEcCtD
Citalopram—Insomnia—Rosuvastatin—atherosclerosis	0.000147	0.000911	CcSEcCtD
Citalopram—Ill-defined disorder—Simvastatin—atherosclerosis	0.000147	0.000908	CcSEcCtD
Citalopram—Arrhythmia—Pravastatin—atherosclerosis	0.000147	0.000908	CcSEcCtD
Citalopram—Palpitations—Ezetimibe—atherosclerosis	0.000147	0.000907	CcSEcCtD
Citalopram—Paraesthesia—Rosuvastatin—atherosclerosis	0.000146	0.000905	CcSEcCtD
Citalopram—Anaemia—Simvastatin—atherosclerosis	0.000146	0.000905	CcSEcCtD
Citalopram—Erythema—Niacin—atherosclerosis	0.000145	0.000899	CcSEcCtD
Citalopram—Malnutrition—Niacin—atherosclerosis	0.000145	0.000899	CcSEcCtD
Citalopram—Alopecia—Pravastatin—atherosclerosis	0.000145	0.000898	CcSEcCtD
Citalopram—Cough—Ezetimibe—atherosclerosis	0.000145	0.000896	CcSEcCtD
Citalopram—Angioedema—Simvastatin—atherosclerosis	0.000145	0.000894	CcSEcCtD
Citalopram—Arthralgia—Lovastatin—atherosclerosis	0.000144	0.000891	CcSEcCtD
Citalopram—Myalgia—Lovastatin—atherosclerosis	0.000144	0.000891	CcSEcCtD
Citalopram—Chest pain—Lovastatin—atherosclerosis	0.000144	0.000891	CcSEcCtD
Citalopram—Anxiety—Lovastatin—atherosclerosis	0.000143	0.000888	CcSEcCtD
Citalopram—Dyspepsia—Rosuvastatin—atherosclerosis	0.000143	0.000887	CcSEcCtD
Citalopram—Hypertension—Ezetimibe—atherosclerosis	0.000143	0.000886	CcSEcCtD
Citalopram—Flatulence—Niacin—atherosclerosis	0.000143	0.000886	CcSEcCtD
Citalopram—Malaise—Simvastatin—atherosclerosis	0.000143	0.000883	CcSEcCtD
Citalopram—Tension—Niacin—atherosclerosis	0.000143	0.000882	CcSEcCtD
Citalopram—Discomfort—Lovastatin—atherosclerosis	0.000142	0.00088	CcSEcCtD
Citalopram—Vertigo—Simvastatin—atherosclerosis	0.000142	0.000879	CcSEcCtD
Citalopram—Leukopenia—Simvastatin—atherosclerosis	0.000142	0.000876	CcSEcCtD
Citalopram—Arthralgia—Ezetimibe—atherosclerosis	0.000141	0.000874	CcSEcCtD
Citalopram—Myalgia—Ezetimibe—atherosclerosis	0.000141	0.000874	CcSEcCtD
Citalopram—Chest pain—Ezetimibe—atherosclerosis	0.000141	0.000874	CcSEcCtD
Citalopram—Nervousness—Niacin—atherosclerosis	0.000141	0.000873	CcSEcCtD
Citalopram—Flatulence—Pravastatin—atherosclerosis	0.000141	0.000872	CcSEcCtD
Citalopram—Dry mouth—Lovastatin—atherosclerosis	0.000141	0.000871	CcSEcCtD
Citalopram—Tension—Pravastatin—atherosclerosis	0.00014	0.000868	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Ezetimibe—atherosclerosis	0.00014	0.000868	CcSEcCtD
Citalopram—Dysgeusia—Pravastatin—atherosclerosis	0.00014	0.000867	CcSEcCtD
Citalopram—Muscle spasms—Niacin—atherosclerosis	0.00014	0.000864	CcSEcCtD
Citalopram—Discomfort—Ezetimibe—atherosclerosis	0.00014	0.000863	CcSEcCtD
Citalopram—Pain—Rosuvastatin—atherosclerosis	0.000139	0.000862	CcSEcCtD
Citalopram—Constipation—Rosuvastatin—atherosclerosis	0.000139	0.000862	CcSEcCtD
Citalopram—Confusional state—Lovastatin—atherosclerosis	0.000139	0.000861	CcSEcCtD
Citalopram—Nervousness—Pravastatin—atherosclerosis	0.000139	0.000859	CcSEcCtD
Citalopram—Dry mouth—Ezetimibe—atherosclerosis	0.000138	0.000855	CcSEcCtD
Citalopram—Anaphylactic shock—Lovastatin—atherosclerosis	0.000138	0.000854	CcSEcCtD
Citalopram—Muscle spasms—Pravastatin—atherosclerosis	0.000137	0.000851	CcSEcCtD
Citalopram—Infection—Lovastatin—atherosclerosis	0.000137	0.000848	CcSEcCtD
Citalopram—Vision blurred—Niacin—atherosclerosis	0.000137	0.000847	CcSEcCtD
Citalopram—Confusional state—Ezetimibe—atherosclerosis	0.000136	0.000845	CcSEcCtD
Citalopram—Anaphylactic shock—Ezetimibe—atherosclerosis	0.000135	0.000838	CcSEcCtD
Citalopram—Thrombocytopenia—Lovastatin—atherosclerosis	0.000135	0.000836	CcSEcCtD
Citalopram—Vision blurred—Pravastatin—atherosclerosis	0.000135	0.000834	CcSEcCtD
Citalopram—Myalgia—Simvastatin—atherosclerosis	0.000135	0.000833	CcSEcCtD
Citalopram—Chest pain—Simvastatin—atherosclerosis	0.000135	0.000833	CcSEcCtD
Citalopram—Arthralgia—Simvastatin—atherosclerosis	0.000135	0.000833	CcSEcCtD
Citalopram—Infection—Ezetimibe—atherosclerosis	0.000134	0.000832	CcSEcCtD
Citalopram—Feeling abnormal—Rosuvastatin—atherosclerosis	0.000134	0.00083	CcSEcCtD
Citalopram—Anxiety—Simvastatin—atherosclerosis	0.000134	0.00083	CcSEcCtD
Citalopram—Tremor—Pravastatin—atherosclerosis	0.000134	0.000829	CcSEcCtD
Citalopram—Gastrointestinal pain—Rosuvastatin—atherosclerosis	0.000133	0.000824	CcSEcCtD
Citalopram—Discomfort—Simvastatin—atherosclerosis	0.000133	0.000823	CcSEcCtD
Citalopram—Nervous system disorder—Ezetimibe—atherosclerosis	0.000133	0.000821	CcSEcCtD
Citalopram—Angioedema—Niacin—atherosclerosis	0.000133	0.000821	CcSEcCtD
Citalopram—Ill-defined disorder—Pravastatin—atherosclerosis	0.000133	0.000821	CcSEcCtD
Citalopram—Thrombocytopenia—Ezetimibe—atherosclerosis	0.000133	0.00082	CcSEcCtD
Citalopram—Anaemia—Pravastatin—atherosclerosis	0.000132	0.000818	CcSEcCtD
Citalopram—Anorexia—Lovastatin—atherosclerosis	0.000132	0.000814	CcSEcCtD
Citalopram—Skin disorder—Ezetimibe—atherosclerosis	0.000131	0.000814	CcSEcCtD
Citalopram—Angioedema—Pravastatin—atherosclerosis	0.000131	0.000809	CcSEcCtD
Citalopram—Vertigo—Niacin—atherosclerosis	0.00013	0.000807	CcSEcCtD
Citalopram—Syncope—Niacin—atherosclerosis	0.00013	0.000806	CcSEcCtD
Citalopram—Confusional state—Simvastatin—atherosclerosis	0.00013	0.000805	CcSEcCtD
Citalopram—Leukopenia—Niacin—atherosclerosis	0.00013	0.000804	CcSEcCtD
Citalopram—Urticaria—Rosuvastatin—atherosclerosis	0.000129	0.000801	CcSEcCtD
Citalopram—Oedema—Simvastatin—atherosclerosis	0.000129	0.000799	CcSEcCtD
Citalopram—Anaphylactic shock—Simvastatin—atherosclerosis	0.000129	0.000799	CcSEcCtD
Citalopram—Malaise—Pravastatin—atherosclerosis	0.000129	0.000798	CcSEcCtD
Citalopram—Abdominal pain—Rosuvastatin—atherosclerosis	0.000129	0.000797	CcSEcCtD
Citalopram—Vertigo—Pravastatin—atherosclerosis	0.000128	0.000795	CcSEcCtD
Citalopram—Palpitations—Niacin—atherosclerosis	0.000128	0.000794	CcSEcCtD
Citalopram—Infection—Simvastatin—atherosclerosis	0.000128	0.000794	CcSEcCtD
Citalopram—Leukopenia—Pravastatin—atherosclerosis	0.000128	0.000792	CcSEcCtD
Citalopram—Loss of consciousness—Niacin—atherosclerosis	0.000128	0.00079	CcSEcCtD
Citalopram—Cough—Niacin—atherosclerosis	0.000127	0.000784	CcSEcCtD
Citalopram—Thrombocytopenia—Simvastatin—atherosclerosis	0.000126	0.000782	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Lovastatin—atherosclerosis	0.000126	0.000778	CcSEcCtD
Citalopram—Insomnia—Lovastatin—atherosclerosis	0.000125	0.000772	CcSEcCtD
Citalopram—Cough—Pravastatin—atherosclerosis	0.000125	0.000772	CcSEcCtD
Citalopram—Paraesthesia—Lovastatin—atherosclerosis	0.000124	0.000767	CcSEcCtD
Citalopram—Myalgia—Niacin—atherosclerosis	0.000124	0.000765	CcSEcCtD
Citalopram—Arthralgia—Niacin—atherosclerosis	0.000124	0.000765	CcSEcCtD
Citalopram—Hypertension—Pravastatin—atherosclerosis	0.000123	0.000764	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Ezetimibe—atherosclerosis	0.000123	0.000763	CcSEcCtD
Citalopram—Anorexia—Simvastatin—atherosclerosis	0.000123	0.000761	CcSEcCtD
Citalopram—Dyspnoea—Lovastatin—atherosclerosis	0.000123	0.000761	CcSEcCtD
Citalopram—Unspecified disorder of skin and subcutaneous tissue—Niacin—atherosclerosis	0.000123	0.00076	CcSEcCtD
Citalopram—Insomnia—Ezetimibe—atherosclerosis	0.000122	0.000758	CcSEcCtD
Citalopram—Chest pain—Pravastatin—atherosclerosis	0.000122	0.000753	CcSEcCtD
Citalopram—Myalgia—Pravastatin—atherosclerosis	0.000122	0.000753	CcSEcCtD
Citalopram—Arthralgia—Pravastatin—atherosclerosis	0.000122	0.000753	CcSEcCtD
Citalopram—Paraesthesia—Ezetimibe—atherosclerosis	0.000122	0.000752	CcSEcCtD
Citalopram—Dyspepsia—Lovastatin—atherosclerosis	0.000121	0.000752	CcSEcCtD
Citalopram—Anxiety—Pravastatin—atherosclerosis	0.000121	0.000751	CcSEcCtD
Citalopram—Dry mouth—Niacin—atherosclerosis	0.000121	0.000748	CcSEcCtD
Citalopram—Dyspnoea—Ezetimibe—atherosclerosis	0.000121	0.000747	CcSEcCtD
Citalopram—Discomfort—Pravastatin—atherosclerosis	0.00012	0.000744	CcSEcCtD
Citalopram—Hypersensitivity—Rosuvastatin—atherosclerosis	0.00012	0.000742	CcSEcCtD
Citalopram—Decreased appetite—Lovastatin—atherosclerosis	0.00012	0.000742	CcSEcCtD
Citalopram—Dyspepsia—Ezetimibe—atherosclerosis	0.000119	0.000737	CcSEcCtD
Citalopram—Fatigue—Lovastatin—atherosclerosis	0.000119	0.000736	CcSEcCtD
Citalopram—Oedema—Niacin—atherosclerosis	0.000119	0.000734	CcSEcCtD
Citalopram—Anaphylactic shock—Niacin—atherosclerosis	0.000119	0.000734	CcSEcCtD
Citalopram—Pain—Lovastatin—atherosclerosis	0.000118	0.00073	CcSEcCtD
Citalopram—Constipation—Lovastatin—atherosclerosis	0.000118	0.00073	CcSEcCtD
Citalopram—Confusional state—Pravastatin—atherosclerosis	0.000118	0.000728	CcSEcCtD
Citalopram—Decreased appetite—Ezetimibe—atherosclerosis	0.000118	0.000728	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Simvastatin—atherosclerosis	0.000118	0.000728	CcSEcCtD
Citalopram—Gastrointestinal disorder—Ezetimibe—atherosclerosis	0.000117	0.000723	CcSEcCtD
Citalopram—Asthenia—Rosuvastatin—atherosclerosis	0.000117	0.000723	CcSEcCtD
Citalopram—Insomnia—Simvastatin—atherosclerosis	0.000117	0.000723	CcSEcCtD
Citalopram—Oedema—Pravastatin—atherosclerosis	0.000117	0.000722	CcSEcCtD
Citalopram—Anaphylactic shock—Pravastatin—atherosclerosis	0.000117	0.000722	CcSEcCtD
Citalopram—Fatigue—Ezetimibe—atherosclerosis	0.000117	0.000722	CcSEcCtD
Citalopram—Shock—Niacin—atherosclerosis	0.000117	0.000722	CcSEcCtD
Citalopram—Infection—Pravastatin—atherosclerosis	0.000116	0.000717	CcSEcCtD
Citalopram—Paraesthesia—Simvastatin—atherosclerosis	0.000116	0.000717	CcSEcCtD
Citalopram—Constipation—Ezetimibe—atherosclerosis	0.000116	0.000716	CcSEcCtD
Citalopram—Pain—Ezetimibe—atherosclerosis	0.000116	0.000716	CcSEcCtD
Citalopram—Tachycardia—Niacin—atherosclerosis	0.000116	0.000716	CcSEcCtD
Citalopram—Pruritus—Rosuvastatin—atherosclerosis	0.000115	0.000713	CcSEcCtD
Citalopram—Skin disorder—Niacin—atherosclerosis	0.000115	0.000712	CcSEcCtD
Citalopram—Dyspnoea—Simvastatin—atherosclerosis	0.000115	0.000712	CcSEcCtD
Citalopram—Hyperhidrosis—Niacin—atherosclerosis	0.000115	0.000709	CcSEcCtD
Citalopram—Thrombocytopenia—Pravastatin—atherosclerosis	0.000114	0.000707	CcSEcCtD
Citalopram—Feeling abnormal—Lovastatin—atherosclerosis	0.000114	0.000704	CcSEcCtD
Citalopram—Dyspepsia—Simvastatin—atherosclerosis	0.000114	0.000703	CcSEcCtD
Citalopram—Anorexia—Niacin—atherosclerosis	0.000113	0.000699	CcSEcCtD
Citalopram—Gastrointestinal pain—Lovastatin—atherosclerosis	0.000113	0.000698	CcSEcCtD
Citalopram—Hyperhidrosis—Pravastatin—atherosclerosis	0.000113	0.000698	CcSEcCtD
Citalopram—Decreased appetite—Simvastatin—atherosclerosis	0.000112	0.000694	CcSEcCtD
Citalopram—Feeling abnormal—Ezetimibe—atherosclerosis	0.000112	0.00069	CcSEcCtD
Citalopram—Gastrointestinal disorder—Simvastatin—atherosclerosis	0.000111	0.00069	CcSEcCtD
Citalopram—Diarrhoea—Rosuvastatin—atherosclerosis	0.000111	0.00069	CcSEcCtD
Citalopram—Fatigue—Simvastatin—atherosclerosis	0.000111	0.000689	CcSEcCtD
Citalopram—Anorexia—Pravastatin—atherosclerosis	0.000111	0.000688	CcSEcCtD
Citalopram—Hypotension—Niacin—atherosclerosis	0.000111	0.000685	CcSEcCtD
Citalopram—Gastrointestinal pain—Ezetimibe—atherosclerosis	0.000111	0.000685	CcSEcCtD
Citalopram—Constipation—Simvastatin—atherosclerosis	0.00011	0.000683	CcSEcCtD
Citalopram—Pain—Simvastatin—atherosclerosis	0.00011	0.000683	CcSEcCtD
Citalopram—Urticaria—Lovastatin—atherosclerosis	0.00011	0.000678	CcSEcCtD
Citalopram—Abdominal pain—Lovastatin—atherosclerosis	0.000109	0.000675	CcSEcCtD
Citalopram—Body temperature increased—Lovastatin—atherosclerosis	0.000109	0.000675	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Niacin—atherosclerosis	0.000108	0.000668	CcSEcCtD
Citalopram—Dizziness—Rosuvastatin—atherosclerosis	0.000108	0.000666	CcSEcCtD
Citalopram—Urticaria—Ezetimibe—atherosclerosis	0.000108	0.000665	CcSEcCtD
Citalopram—Insomnia—Niacin—atherosclerosis	0.000107	0.000663	CcSEcCtD
Citalopram—Body temperature increased—Ezetimibe—atherosclerosis	0.000107	0.000662	CcSEcCtD
Citalopram—Abdominal pain—Ezetimibe—atherosclerosis	0.000107	0.000662	CcSEcCtD
Citalopram—Paraesthesia—Niacin—atherosclerosis	0.000106	0.000659	CcSEcCtD
Citalopram—Feeling abnormal—Simvastatin—atherosclerosis	0.000106	0.000658	CcSEcCtD
Citalopram—Musculoskeletal discomfort—Pravastatin—atherosclerosis	0.000106	0.000658	CcSEcCtD
Citalopram—Dyspnoea—Niacin—atherosclerosis	0.000106	0.000654	CcSEcCtD
Citalopram—Gastrointestinal pain—Simvastatin—atherosclerosis	0.000106	0.000653	CcSEcCtD
Citalopram—Insomnia—Pravastatin—atherosclerosis	0.000106	0.000653	CcSEcCtD
Citalopram—Somnolence—Niacin—atherosclerosis	0.000105	0.000652	CcSEcCtD
Citalopram—Paraesthesia—Pravastatin—atherosclerosis	0.000105	0.000649	CcSEcCtD
Citalopram—Dyspepsia—Niacin—atherosclerosis	0.000104	0.000646	CcSEcCtD
Citalopram—Dyspnoea—Pravastatin—atherosclerosis	0.000104	0.000644	CcSEcCtD
Citalopram—Decreased appetite—Niacin—atherosclerosis	0.000103	0.000638	CcSEcCtD
Citalopram—Dyspepsia—Pravastatin—atherosclerosis	0.000103	0.000636	CcSEcCtD
Citalopram—Rash—Rosuvastatin—atherosclerosis	0.000103	0.000635	CcSEcCtD
Citalopram—Dermatitis—Rosuvastatin—atherosclerosis	0.000103	0.000635	CcSEcCtD
Citalopram—Urticaria—Simvastatin—atherosclerosis	0.000103	0.000635	CcSEcCtD
Citalopram—Gastrointestinal disorder—Niacin—atherosclerosis	0.000102	0.000633	CcSEcCtD
Citalopram—Body temperature increased—Simvastatin—atherosclerosis	0.000102	0.000631	CcSEcCtD
Citalopram—Abdominal pain—Simvastatin—atherosclerosis	0.000102	0.000631	CcSEcCtD
Citalopram—Headache—Rosuvastatin—atherosclerosis	0.000102	0.000631	CcSEcCtD
Citalopram—Hypersensitivity—Lovastatin—atherosclerosis	0.000102	0.000629	CcSEcCtD
Citalopram—Decreased appetite—Pravastatin—atherosclerosis	0.000101	0.000628	CcSEcCtD
Citalopram—Pain—Niacin—atherosclerosis	0.000101	0.000627	CcSEcCtD
Citalopram—Fatigue—Pravastatin—atherosclerosis	0.000101	0.000623	CcSEcCtD
Citalopram—Pain—Pravastatin—atherosclerosis	9.98e-05	0.000618	CcSEcCtD
Citalopram—Constipation—Pravastatin—atherosclerosis	9.98e-05	0.000618	CcSEcCtD
Citalopram—Hypersensitivity—Ezetimibe—atherosclerosis	9.97e-05	0.000617	CcSEcCtD
Citalopram—Asthenia—Lovastatin—atherosclerosis	9.9e-05	0.000613	CcSEcCtD
Citalopram—Pruritus—Lovastatin—atherosclerosis	9.76e-05	0.000604	CcSEcCtD
Citalopram—Asthenia—Ezetimibe—atherosclerosis	9.71e-05	0.000601	CcSEcCtD
Citalopram—Gastrointestinal pain—Niacin—atherosclerosis	9.69e-05	0.0006	CcSEcCtD
Citalopram—Nausea—Rosuvastatin—atherosclerosis	9.67e-05	0.000599	CcSEcCtD
Citalopram—Feeling abnormal—Pravastatin—atherosclerosis	9.62e-05	0.000595	CcSEcCtD
Citalopram—Pruritus—Ezetimibe—atherosclerosis	9.58e-05	0.000593	CcSEcCtD
Citalopram—Gastrointestinal pain—Pravastatin—atherosclerosis	9.54e-05	0.000591	CcSEcCtD
Citalopram—Hypersensitivity—Simvastatin—atherosclerosis	9.51e-05	0.000589	CcSEcCtD
Citalopram—Diarrhoea—Lovastatin—atherosclerosis	9.44e-05	0.000584	CcSEcCtD
Citalopram—Urticaria—Niacin—atherosclerosis	9.42e-05	0.000583	CcSEcCtD
Citalopram—Abdominal pain—Niacin—atherosclerosis	9.37e-05	0.00058	CcSEcCtD
Citalopram—Body temperature increased—Niacin—atherosclerosis	9.37e-05	0.00058	CcSEcCtD
Citalopram—Urticaria—Pravastatin—atherosclerosis	9.27e-05	0.000574	CcSEcCtD
Citalopram—Asthenia—Simvastatin—atherosclerosis	9.26e-05	0.000573	CcSEcCtD
Citalopram—Diarrhoea—Ezetimibe—atherosclerosis	9.26e-05	0.000573	CcSEcCtD
Citalopram—Body temperature increased—Pravastatin—atherosclerosis	9.23e-05	0.000571	CcSEcCtD
Citalopram—Abdominal pain—Pravastatin—atherosclerosis	9.23e-05	0.000571	CcSEcCtD
Citalopram—Pruritus—Simvastatin—atherosclerosis	9.13e-05	0.000565	CcSEcCtD
Citalopram—Dizziness—Lovastatin—atherosclerosis	9.13e-05	0.000565	CcSEcCtD
Citalopram—Dizziness—Ezetimibe—atherosclerosis	8.95e-05	0.000554	CcSEcCtD
Citalopram—Diarrhoea—Simvastatin—atherosclerosis	8.83e-05	0.000547	CcSEcCtD
Citalopram—Vomiting—Lovastatin—atherosclerosis	8.77e-05	0.000543	CcSEcCtD
Citalopram—Hypersensitivity—Niacin—atherosclerosis	8.73e-05	0.00054	CcSEcCtD
Citalopram—Rash—Lovastatin—atherosclerosis	8.7e-05	0.000538	CcSEcCtD
Citalopram—Dermatitis—Lovastatin—atherosclerosis	8.69e-05	0.000538	CcSEcCtD
Citalopram—Headache—Lovastatin—atherosclerosis	8.65e-05	0.000535	CcSEcCtD
Citalopram—Vomiting—Ezetimibe—atherosclerosis	8.61e-05	0.000533	CcSEcCtD
Citalopram—Hypersensitivity—Pravastatin—atherosclerosis	8.6e-05	0.000532	CcSEcCtD
Citalopram—Dizziness—Simvastatin—atherosclerosis	8.54e-05	0.000528	CcSEcCtD
Citalopram—Rash—Ezetimibe—atherosclerosis	8.53e-05	0.000528	CcSEcCtD
Citalopram—Dermatitis—Ezetimibe—atherosclerosis	8.53e-05	0.000528	CcSEcCtD
Citalopram—Asthenia—Niacin—atherosclerosis	8.5e-05	0.000526	CcSEcCtD
Citalopram—Headache—Ezetimibe—atherosclerosis	8.48e-05	0.000525	CcSEcCtD
Citalopram—Pruritus—Niacin—atherosclerosis	8.39e-05	0.000519	CcSEcCtD
Citalopram—Asthenia—Pravastatin—atherosclerosis	8.37e-05	0.000518	CcSEcCtD
Citalopram—Pruritus—Pravastatin—atherosclerosis	8.26e-05	0.000511	CcSEcCtD
Citalopram—Vomiting—Simvastatin—atherosclerosis	8.21e-05	0.000508	CcSEcCtD
Citalopram—Nausea—Lovastatin—atherosclerosis	8.2e-05	0.000507	CcSEcCtD
Citalopram—Rash—Simvastatin—atherosclerosis	8.14e-05	0.000504	CcSEcCtD
Citalopram—Dermatitis—Simvastatin—atherosclerosis	8.13e-05	0.000503	CcSEcCtD
Citalopram—Diarrhoea—Niacin—atherosclerosis	8.11e-05	0.000502	CcSEcCtD
Citalopram—Headache—Simvastatin—atherosclerosis	8.09e-05	0.0005	CcSEcCtD
Citalopram—Nausea—Ezetimibe—atherosclerosis	8.04e-05	0.000498	CcSEcCtD
Citalopram—Diarrhoea—Pravastatin—atherosclerosis	7.99e-05	0.000494	CcSEcCtD
Citalopram—Dizziness—Niacin—atherosclerosis	7.84e-05	0.000485	CcSEcCtD
Citalopram—Dizziness—Pravastatin—atherosclerosis	7.72e-05	0.000478	CcSEcCtD
Citalopram—Nausea—Simvastatin—atherosclerosis	7.67e-05	0.000474	CcSEcCtD
Citalopram—Vomiting—Niacin—atherosclerosis	7.54e-05	0.000466	CcSEcCtD
Citalopram—Rash—Niacin—atherosclerosis	7.47e-05	0.000462	CcSEcCtD
Citalopram—Dermatitis—Niacin—atherosclerosis	7.47e-05	0.000462	CcSEcCtD
Citalopram—Headache—Niacin—atherosclerosis	7.43e-05	0.00046	CcSEcCtD
Citalopram—Vomiting—Pravastatin—atherosclerosis	7.42e-05	0.000459	CcSEcCtD
Citalopram—Rash—Pravastatin—atherosclerosis	7.36e-05	0.000455	CcSEcCtD
Citalopram—Dermatitis—Pravastatin—atherosclerosis	7.35e-05	0.000455	CcSEcCtD
Citalopram—Headache—Pravastatin—atherosclerosis	7.31e-05	0.000452	CcSEcCtD
Citalopram—Nausea—Niacin—atherosclerosis	7.04e-05	0.000436	CcSEcCtD
Citalopram—Nausea—Pravastatin—atherosclerosis	6.93e-05	0.000429	CcSEcCtD
Citalopram—CHRM1—Signaling Pathways—SPP1—atherosclerosis	5.73e-06	0.0001	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—CXCL8—atherosclerosis	5.72e-06	0.0001	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—CXCL8—atherosclerosis	5.7e-06	0.0001	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SPP1—atherosclerosis	5.64e-06	9.89e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—BGN—atherosclerosis	5.63e-06	9.87e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—CXCL8—atherosclerosis	5.61e-06	9.84e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—ESR1—atherosclerosis	5.6e-06	9.82e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—MTHFR—atherosclerosis	5.58e-06	9.79e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOA5—atherosclerosis	5.57e-06	9.77e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—F2—atherosclerosis	5.53e-06	9.7e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—SCARB1—atherosclerosis	5.53e-06	9.69e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ABCA1—atherosclerosis	5.49e-06	9.63e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARA—atherosclerosis	5.48e-06	9.61e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—MTHFR—atherosclerosis	5.47e-06	9.59e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—ALB—atherosclerosis	5.38e-06	9.44e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARA—atherosclerosis	5.36e-06	9.41e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PLA2G1B—atherosclerosis	5.36e-06	9.41e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PDGFB—atherosclerosis	5.31e-06	9.32e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AGT—atherosclerosis	5.3e-06	9.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PDGFB—atherosclerosis	5.3e-06	9.29e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—PIK3CG—atherosclerosis	5.29e-06	9.29e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HMGCR—atherosclerosis	5.22e-06	9.15e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PDGFB—atherosclerosis	5.22e-06	9.15e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APOE—atherosclerosis	5.2e-06	9.11e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AGT—atherosclerosis	5.19e-06	9.11e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AGT—atherosclerosis	5.19e-06	9.1e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALOX5—atherosclerosis	5.18e-06	9.08e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AGT—atherosclerosis	5.17e-06	9.07e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—CAV1—atherosclerosis	5.15e-06	9.03e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—APOA1—atherosclerosis	5.14e-06	9.01e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—HMOX1—atherosclerosis	5.12e-06	8.98e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AGT—atherosclerosis	5.09e-06	8.93e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APOE—atherosclerosis	5.09e-06	8.93e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APOE—atherosclerosis	5.08e-06	8.92e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—LEP—atherosclerosis	5.08e-06	8.92e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—MAPK3—atherosclerosis	5.07e-06	8.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—LEP—atherosclerosis	5.07e-06	8.89e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APOE—atherosclerosis	5.07e-06	8.89e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—CAV1—atherosclerosis	5.04e-06	8.85e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CAV1—atherosclerosis	5.04e-06	8.83e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—APOA1—atherosclerosis	5.03e-06	8.83e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—APOA1—atherosclerosis	5.03e-06	8.81e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CAV1—atherosclerosis	5.02e-06	8.81e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—INS—atherosclerosis	5.01e-06	8.79e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—APOA1—atherosclerosis	5.01e-06	8.79e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—HMOX1—atherosclerosis	5e-06	8.77e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APOE—atherosclerosis	4.99e-06	8.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—LEP—atherosclerosis	4.99e-06	8.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CAV1—atherosclerosis	4.94e-06	8.67e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—APOA1—atherosclerosis	4.93e-06	8.65e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CCL2—atherosclerosis	4.93e-06	8.65e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOB—atherosclerosis	4.91e-06	8.61e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—ESR1—atherosclerosis	4.85e-06	8.51e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IGF1—atherosclerosis	4.85e-06	8.5e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—ESR1—atherosclerosis	4.84e-06	8.49e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—F2—atherosclerosis	4.79e-06	8.41e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOB—atherosclerosis	4.79e-06	8.4e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—F2—atherosclerosis	4.78e-06	8.38e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GSTM1—atherosclerosis	4.77e-06	8.37e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—ESR1—atherosclerosis	4.76e-06	8.35e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—HMOX1—atherosclerosis	4.71e-06	8.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—atherosclerosis	4.71e-06	8.26e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—F2—atherosclerosis	4.7e-06	8.25e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PIK3CG—atherosclerosis	4.69e-06	8.23e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—LPL—atherosclerosis	4.68e-06	8.22e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GSTM1—atherosclerosis	4.66e-06	8.17e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ABCA1—atherosclerosis	4.65e-06	8.16e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NAMPT—atherosclerosis	4.65e-06	8.15e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—LIPC—atherosclerosis	4.62e-06	8.1e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—SERPINE1—atherosclerosis	4.6e-06	8.07e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PIK3CG—atherosclerosis	4.59e-06	8.06e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOC3—atherosclerosis	4.59e-06	8.05e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—PIK3CG—atherosclerosis	4.59e-06	8.05e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—PIK3CG—atherosclerosis	4.57e-06	8.02e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—LPL—atherosclerosis	4.57e-06	8.02e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—GPX1—atherosclerosis	4.57e-06	8.02e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—LDLR—atherosclerosis	4.56e-06	8e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PPARG—atherosclerosis	4.53e-06	7.94e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOB—atherosclerosis	4.51e-06	7.92e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—PIK3CG—atherosclerosis	4.5e-06	7.9e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—GPX1—atherosclerosis	4.46e-06	7.82e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CETP—atherosclerosis	4.45e-06	7.81e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CD36—atherosclerosis	4.45e-06	7.81e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—INS—atherosclerosis	4.44e-06	7.79e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PPARG—atherosclerosis	4.43e-06	7.78e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NOS3—atherosclerosis	4.4e-06	7.71e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—MAPK3—atherosclerosis	4.39e-06	7.71e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GSTM1—atherosclerosis	4.39e-06	7.7e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—MAPK3—atherosclerosis	4.38e-06	7.68e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—INS—atherosclerosis	4.35e-06	7.63e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CD36—atherosclerosis	4.34e-06	7.62e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—INS—atherosclerosis	4.34e-06	7.62e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—INS—atherosclerosis	4.33e-06	7.59e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—MAPK3—atherosclerosis	4.31e-06	7.56e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—LPL—atherosclerosis	4.31e-06	7.56e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CCL2—atherosclerosis	4.27e-06	7.49e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—SCARB1—atherosclerosis	4.27e-06	7.48e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—INS—atherosclerosis	4.26e-06	7.47e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CCL2—atherosclerosis	4.26e-06	7.47e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—MTHFR—atherosclerosis	4.22e-06	7.4e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—GPX1—atherosclerosis	4.2e-06	7.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IGF1—atherosclerosis	4.2e-06	7.37e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CCL2—atherosclerosis	4.19e-06	7.35e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IGF1—atherosclerosis	4.19e-06	7.34e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARA—atherosclerosis	4.14e-06	7.26e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IGF1—atherosclerosis	4.12e-06	7.23e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—MTHFR—atherosclerosis	4.12e-06	7.22e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CD36—atherosclerosis	4.09e-06	7.18e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—ALB—atherosclerosis	4.07e-06	7.14e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARA—atherosclerosis	4.04e-06	7.08e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HMGCR—atherosclerosis	4.03e-06	7.07e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AGT—atherosclerosis	4.01e-06	7.03e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—HMOX1—atherosclerosis	3.99e-06	7e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—SERPINE1—atherosclerosis	3.99e-06	7e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—ALB—atherosclerosis	3.99e-06	6.99e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—SERPINE1—atherosclerosis	3.98e-06	6.97e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOE—atherosclerosis	3.93e-06	6.89e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—SERPINE1—atherosclerosis	3.91e-06	6.87e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AGT—atherosclerosis	3.91e-06	6.86e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—CXCL8—atherosclerosis	3.9e-06	6.84e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—NOS3—atherosclerosis	3.89e-06	6.83e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—CAV1—atherosclerosis	3.89e-06	6.82e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—APOA1—atherosclerosis	3.88e-06	6.81e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—MTHFR—atherosclerosis	3.88e-06	6.8e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOE—atherosclerosis	3.83e-06	6.72e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOB—atherosclerosis	3.82e-06	6.71e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—NOS3—atherosclerosis	3.81e-06	6.69e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NOS3—atherosclerosis	3.81e-06	6.68e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARA—atherosclerosis	3.81e-06	6.68e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—CAV1—atherosclerosis	3.8e-06	6.66e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NOS3—atherosclerosis	3.8e-06	6.66e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—APOA1—atherosclerosis	3.79e-06	6.65e-05	CbGpPWpGaD
Citalopram—HTR2C—GPCR downstream signaling—AKT1—atherosclerosis	3.77e-06	6.61e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NOS3—atherosclerosis	3.74e-06	6.55e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GSTM1—atherosclerosis	3.72e-06	6.52e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—IL6—atherosclerosis	3.71e-06	6.5e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AGT—atherosclerosis	3.69e-06	6.47e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—LPL—atherosclerosis	3.65e-06	6.4e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOE—atherosclerosis	3.61e-06	6.34e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ABCA1—atherosclerosis	3.59e-06	6.3e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—CAV1—atherosclerosis	3.58e-06	6.28e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—APOA1—atherosclerosis	3.57e-06	6.26e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—GPX1—atherosclerosis	3.56e-06	6.25e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—PTGS2—atherosclerosis	3.56e-06	6.25e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PIK3CG—atherosclerosis	3.54e-06	6.22e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MMP9—atherosclerosis	3.53e-06	6.18e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—NFKB1—atherosclerosis	3.49e-06	6.12e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—PTGS2—atherosclerosis	3.49e-06	6.12e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CD36—atherosclerosis	3.47e-06	6.08e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PIK3CG—atherosclerosis	3.46e-06	6.07e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK8—atherosclerosis	3.43e-06	6.02e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PPARG—atherosclerosis	3.42e-06	6e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling by GPCR—AKT1—atherosclerosis	3.42e-06	6e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—CXCL8—atherosclerosis	3.38e-06	5.93e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—CXCL8—atherosclerosis	3.37e-06	5.91e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—INS—atherosclerosis	3.35e-06	5.88e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PPARG—atherosclerosis	3.34e-06	5.86e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—CXCL8—atherosclerosis	3.31e-06	5.81e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—MTHFR—atherosclerosis	3.29e-06	5.76e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—INS—atherosclerosis	3.27e-06	5.74e-05	CbGpPWpGaD
Citalopram—HRH1—GPCR downstream signaling—AKT1—atherosclerosis	3.26e-06	5.72e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PIK3CG—atherosclerosis	3.26e-06	5.72e-05	CbGpPWpGaD
Citalopram—CHRM1—GPCR downstream signaling—AKT1—atherosclerosis	3.25e-06	5.71e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARA—atherosclerosis	3.22e-06	5.66e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—IL6—atherosclerosis	3.21e-06	5.63e-05	CbGpPWpGaD
Citalopram—ADRA1A—GPCR downstream signaling—AKT1—atherosclerosis	3.2e-06	5.62e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—IL6—atherosclerosis	3.2e-06	5.62e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—VEGFA—atherosclerosis	3.17e-06	5.55e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—IL6—atherosclerosis	3.15e-06	5.53e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PPARG—atherosclerosis	3.15e-06	5.52e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—STAT3—atherosclerosis	3.14e-06	5.5e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AGT—atherosclerosis	3.12e-06	5.48e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—INS—atherosclerosis	3.09e-06	5.41e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—HMOX1—atherosclerosis	3.08e-06	5.4e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—ALB—atherosclerosis	3.08e-06	5.39e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOE—atherosclerosis	3.06e-06	5.37e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MMP9—atherosclerosis	3.06e-06	5.36e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MMP9—atherosclerosis	3.05e-06	5.34e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—CAV1—atherosclerosis	3.03e-06	5.32e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—APOA1—atherosclerosis	3.02e-06	5.31e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—NFKB1—atherosclerosis	3.02e-06	5.3e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—NFKB1—atherosclerosis	3.01e-06	5.29e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—ALB—atherosclerosis	3e-06	5.27e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MMP9—atherosclerosis	3e-06	5.26e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—MAPK3—atherosclerosis	3e-06	5.25e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK8—atherosclerosis	2.97e-06	5.21e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—NFKB1—atherosclerosis	2.97e-06	5.2e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling by GPCR—AKT1—atherosclerosis	2.96e-06	5.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK8—atherosclerosis	2.96e-06	5.2e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling by GPCR—AKT1—atherosclerosis	2.95e-06	5.18e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOB—atherosclerosis	2.95e-06	5.18e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—NOS3—atherosclerosis	2.94e-06	5.16e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK8—atherosclerosis	2.92e-06	5.11e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling by GPCR—AKT1—atherosclerosis	2.91e-06	5.1e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—TGFB1—atherosclerosis	2.91e-06	5.1e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—NOS3—atherosclerosis	2.87e-06	5.04e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GSTM1—atherosclerosis	2.87e-06	5.03e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—ALB—atherosclerosis	2.83e-06	4.96e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—LPL—atherosclerosis	2.82e-06	4.94e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PIK3CG—atherosclerosis	2.76e-06	4.84e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—GPX1—atherosclerosis	2.75e-06	4.82e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—VEGFA—atherosclerosis	2.74e-06	4.81e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—VEGFA—atherosclerosis	2.73e-06	4.8e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—STAT3—atherosclerosis	2.72e-06	4.77e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—STAT3—atherosclerosis	2.71e-06	4.75e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—NOS3—atherosclerosis	2.71e-06	4.75e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—VEGFA—atherosclerosis	2.69e-06	4.72e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—PTGS2—atherosclerosis	2.69e-06	4.72e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CD36—atherosclerosis	2.68e-06	4.7e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—STAT3—atherosclerosis	2.67e-06	4.68e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PPARG—atherosclerosis	2.67e-06	4.67e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—PTGS2—atherosclerosis	2.63e-06	4.61e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—INS—atherosclerosis	2.61e-06	4.58e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—MAPK3—atherosclerosis	2.6e-06	4.55e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—MAPK3—atherosclerosis	2.59e-06	4.54e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—MAPK3—atherosclerosis	2.55e-06	4.47e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—MTHFR—atherosclerosis	2.54e-06	4.45e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—TGFB1—atherosclerosis	2.52e-06	4.42e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—TGFB1—atherosclerosis	2.51e-06	4.4e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARA—atherosclerosis	2.49e-06	4.36e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—PTGS2—atherosclerosis	2.47e-06	4.34e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—TGFB1—atherosclerosis	2.47e-06	4.33e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AGT—atherosclerosis	2.41e-06	4.23e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—ALB—atherosclerosis	2.4e-06	4.2e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOE—atherosclerosis	2.36e-06	4.14e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—CAV1—atherosclerosis	2.34e-06	4.1e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—APOA1—atherosclerosis	2.33e-06	4.09e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—NOS3—atherosclerosis	2.29e-06	4.02e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—IL6—atherosclerosis	2.19e-06	3.84e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PIK3CG—atherosclerosis	2.13e-06	3.74e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—PTGS2—atherosclerosis	2.1e-06	3.68e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PPARG—atherosclerosis	2.06e-06	3.61e-05	CbGpPWpGaD
Citalopram—HTR2C—Signaling Pathways—AKT1—atherosclerosis	2.02e-06	3.54e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—INS—atherosclerosis	2.02e-06	3.54e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—IL6—atherosclerosis	1.9e-06	3.33e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—IL6—atherosclerosis	1.89e-06	3.32e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—IL6—atherosclerosis	1.86e-06	3.27e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—ALB—atherosclerosis	1.85e-06	3.24e-05	CbGpPWpGaD
Citalopram—CYP2B6—Metabolism—AKT1—atherosclerosis	1.79e-06	3.14e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—NOS3—atherosclerosis	1.77e-06	3.1e-05	CbGpPWpGaD
Citalopram—CYP2E1—Metabolism—AKT1—atherosclerosis	1.75e-06	3.07e-05	CbGpPWpGaD
Citalopram—HRH1—Signaling Pathways—AKT1—atherosclerosis	1.75e-06	3.07e-05	CbGpPWpGaD
Citalopram—CHRM1—Signaling Pathways—AKT1—atherosclerosis	1.75e-06	3.06e-05	CbGpPWpGaD
Citalopram—ADRA1A—Signaling Pathways—AKT1—atherosclerosis	1.72e-06	3.01e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—PTGS2—atherosclerosis	1.62e-06	2.84e-05	CbGpPWpGaD
Citalopram—CYP2C19—Metabolism—AKT1—atherosclerosis	1.35e-06	2.37e-05	CbGpPWpGaD
Citalopram—ABCB1—Metabolism—AKT1—atherosclerosis	1.32e-06	2.32e-05	CbGpPWpGaD
Citalopram—CYP2D6—Metabolism—AKT1—atherosclerosis	1.24e-06	2.18e-05	CbGpPWpGaD
Citalopram—CYP1A2—Metabolism—AKT1—atherosclerosis	1.05e-06	1.85e-05	CbGpPWpGaD
Citalopram—CYP3A4—Metabolism—AKT1—atherosclerosis	8.13e-07	1.43e-05	CbGpPWpGaD
